Robert G. Finizio is a Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD. Mr. Finizio has 20 years of medical knowledge and co-founded TherapeuticsMD in 2008, leveraging his entrepreneurial and remedy record credentials into women’s health. Utilizing a Company’s exclusive technologies, Mr. Finizio is heading TherapeuticsMD by a clinical growth and regulatory examination for novel hormone therapy products, targeting large, unmet marketplace needs associated to menopause government globally. In his stream role, Mr. Finizio has lifted some-more than $250 million in collateral for a company. Mr. Finizio is a connoisseur of a University of Miami and taught English in Osaka, Japan before rising his medical career, operative in a Operating Room for Endoscopy Specialist Incorporated (ESI) in Operational, Sales, and Regional Management roles. After ESI, Mr. Finizio assimilated OmniCell Technologies a personality in remedy management. In 2001, Mr. Finizio co-founded remedy and clinical record businessman CareFusion, offered it to Cardinal Health in 2006.
TherapeuticsMD, Inc. is an innovative medical association focused on building and commercializing products exclusively for women. With a SYMBODA™ technology, TherapeuticsMD is building modernized hormone therapy curative products to capacitate smoothness of bio-identical hormones by a accumulation of dose forms and administration routes. The Company’s late theatre clinical tube includes dual proviso 3 product candidates: TX-001HR for diagnosis of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for diagnosis of moderate-to-severe vaginal pain during passionate retort (dyspareunia), a sign of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and general medication prenatal vitamins underneath a vitaMedMD® and BocaGreenMD® brands.